Skip to main content
Premium Trial:

Request an Annual Quote

One BioMed Raises $5M in Series A Round

NEW YORK — Singaporean diagnostics firm One BioMed said today that it has closed a $5 million Series A round of financing.

The round was led by Biopath Ventures Arch and Venture Partners with participation from Singapore government-led investment group Seeds Capital. In conjunction with the round, BioPath's Joseph Jeong and Nick Roelofs will join One BioMed's board.

One BioMed was spun out of Singapore's Agency for Science, Technology, and Research (A*Star) to  develop a point-of-care diagnostic platform for infectious disease that uses chemistry-based nucleic acid extraction and silicon biophotonics dual-ring sensing. 

The company said it will use the Series A funding to commercialize its first product, an automated sample preparation device for the purification and isolation of nucleic acids. It added that the device will be the foundation for future platforms that integrate molecular diagnostic tools.

Late last year, One BioMed and A*Star's Institute of Microelectronics established a joint laboratory in order to launch a rapid point-of-care test that can detect up to 20 infectious diseases simultaneously.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.